SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) September 28,
1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. (Nasdaq:BICO)
announced today that the company has launched a full-scale
financial and public relations program. Fred E. Cooper,
Biocontrol chief executive officer, said the company has retained
Martin E. Janis & Company, Inc. to conduct the campaign to
bring the company's story to the financial and business
communities and the general public. In addition, Martin E.
Janis & Company will assist Biocontrol with locating potential
strategic partners for product sales and funding.
Item 6. Resignation of Registrant's Directors.
Not Applicable.
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: September 28, 1998
BIOCONTROL TECHNOLOGY, INC.
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL RETAINS MARTIN E. JANIS & COMPANY, INC. FOR
FULL-SCALE FINANCIAL AND PUBLIC RELATIONS PROGRAM
Pittsburgh, PA - September 28, 1998 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that the company has launched a
full-scale financial and public relations program.
Fred E. Cooper, Biocontrol chief executive officer, said the
company has retained Martin E. Janis & Company, Inc. to conduct
the campaign to bring the company's story to the financial and
business communities and the general public. In addition, Martin
E. Janis & Company will assist Biocontrol with locating potential
strategic partners for product sales and funding.
Martin E. Janis & Company, Inc., founded in 1950, represents
clients in many fields of endeavor and renders to a "blue chip"
clientele nationwide investor relations and financial public
relations as well as product and marketing services and
publicity.
Biocontrol Technology, Inc. (www.bico.com) has its corporate
offices in Pittsburgh, PA and is involved in the development and
manufacture of biomedical devices and environmental products.
This press release contains forward looking statements and shareholders
and potential investors are cautioned that such statements are predictions
and actual events or results may vary significantly.
